Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tixagevimabum, cilgavimabum - injektionslösung - a): tixagevimabum 150 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.5 ml. b): cilgavimabum 150 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.5 ml. - behandlung und prä-expositionsprophylaxe von covid-19 - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - immunseren und immunglobuline, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immunseren und immunglobuline, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. siehe abschnitte 4. 4 und 5.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - nirsevimabum - solution injectable en seringue préremplie - nirsevimabum 50 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.5 ml. - prévention des maladies à rsv - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - nirsevimabum - solution injectable en seringue préremplie - nirsevimabum 100 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 1 ml. - prévention des maladies à rsv - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - casirivimabum, imdevimabum - injektions-/infusionslösung - a): casirivimabum 120 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. b): imdevimabum 120 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - behandlung und prophylaxe von covid-19 - biotechnologika